Guardant Health and Nuvalent entered a multi-year strategic collaboration to develop and potentially commercialize oncology companion diagnostics. The companies plan to use Guardant’s tissue and liquid biopsy portfolio to support specific Nuvalent global clinical oncology studies and to evaluate companion diagnostic opportunities for Nuvalent’s investigational candidates. The agreement also covers commercialization planning if candidates receive regulatory approval, pairing Guardant assay capabilities with Nuvalent’s precision oncology development strategy. For developers of molecularly targeted oncology drugs, the collaboration reiterates how co-development of diagnostics is becoming part of the pipeline strategy—linked to both trial enrollment and post-approval labeling expectations.